Ravulizumab Subcutaneous (SC) Versus Ravulizumab Intravenous (IV) in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Eculizumab

NCT03748823 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

139

Enrollment

INDUSTRY

Sponsor class

Conditions

Paroxysmal Nocturnal Hemoglobinuria

Interventions

COMBINATION_PRODUCT: Ravulizumab OBDS
BIOLOGICAL: Ravulizumab

Sponsor

Alexion Pharmaceuticals, Inc.